Effects of GLP-1 Agonist and SGLT2 Inhibitor on Cardiovascular Health in Diabetic Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines the cardiovascular effects of GLP-1 agonists and SGLT2 inhibitors in patients with type 2 diabetes mellitus who are at high cardiovascular risk or have heart failure with preserved ejection fraction. It involves four groups of patients receiving different combinations of diabetes medications over a 12-month period. The study aims to assess changes in endothelial glycocalyx integrity, oxidative stress biomarkers, arterial stiffness, and other cardiovascular indicators. Participants will be monitored at baseline, 6 months, and 12 months to evaluate the effectiveness of the treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject has type 2 diabetes mellitus
* Subject has high or very high cardiovascular risk
* Subject has heart failure with preserved ejection fraction

Exclusion Criteria:

* Subject has type 1 diabetes mellitus
* Subject has kidney disease
* Subject has retinopathy

Where it's running

• "Attikon" University General Hospital
  Athens, Attica, Greece Recruiting

Study contacts

• Principal investigator: Ignatios Ikonomidis, Prof — 2nd Department of Cardiology, National and Kapodistrian University of Athens
• Study coordinator: Ignatios Ikonomidis, Prof.
• Email: ignoik@gmail.com
• Phone: 00306944805732

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proliverenol for liver fat and insulin resistance in type 2 diabetes

  This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.

  Recruiting Phase 2 Universitas Sriwijaya · Palembang, South Sumatera · NCT07928661

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

  This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.

  Recruiting Bionime Corporation · Ulm, Baden-Wurttemberg · NCT07889388

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.